TREACE MEDICAL CONCEPTS INC
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
TMCI$4.88+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(18,676) | $(13,454) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization expense | 1,909 | 924 |
| Provision for allowance for doubtful accounts | 159 | 38 |
| Share-based compensation expense | 7,408 | 2,692 |
| Non-cash lease expense | 592 | 626 |
| Amortization of debt issuance costs | 75 | 74 |
| Recovery of loss reserve for surgical instruments | — | (23) |
| Accretion (amortization) of discount (premium) on marketable securities, net | (335) | (297) |
| Other, net | 90 | — |
| Net changes in operating assets and liabilities, net of acquisitions | ||
| Accounts receivable | 7,821 | 3,793 |
| Inventory | (6,615) | (3,189) |
| Prepaid expenses and other assets | (1,495) | (963) |
| Other non-current assets | — | (69) |
| Payable to broker for unsettled marketable security purchases | — | 710 |
| Operating lease liabilities | (657) | (478) |
| Accounts payable | 9,314 | (3,592) |
| Accrued liabilities | (6,918) | (4,076) |
| Other, net | 107 | 25 |
| Net cash used in operating activities | (7,221) | (17,259) |
| Cash flows from investing activities | ||
| Purchases of available-for-sale marketable securities | (28,711) | (99,550) |
| Sales and maturities of available-for-sale marketable securities | 36,396 | 20,548 |
| Purchases of property and equipment | (3,927) | (1,478) |
| Net cash provided by (used in) investing activities | 3,758 | (80,480) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock from public offering, net of issuance costs and underwriting discount of $7.5 million and $10.6 million | — | 107,527 |
| Proceeds from exercise of employee stock options | 52 | 352 |
| Taxes from withheld shares | (237) | — |
| Net cash provided by (used in) financing activities | (185) | 107,879 |
| Net increase (decrease) in cash and cash equivalents | (3,648) | 10,140 |
| Cash and cash equivalents at beginning of period | 12,982 | 19,473 |
| Cash and cash equivalents at end of period | $9,334 | $29,613 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $1,317 | $1,285 |
| Operating lease right-of-use asset and lease liability adjustment due to lease incentive | $— | $(35) |
| Noncash investing activities | ||
| Unrealized (gains) losses, net on marketable securities | $94 | $29 |
| Unsettled matured marketable security and receivable from broker | $2,100 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.